Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

That’s why one of the most closely watched elements of a company’s earnings report is the guidance it gives for the next quarter or year. We’re still midway through the current earnings season, but ...

One of the highlights of Eli Lilly's third-quarter results was ... with fewer than 10% switching from Trulicity, said Lilly's chief financial officer Anat Ashkenazi on the call.

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...